<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 4, 2020 (HealthDay News) — For patients with atherosclerotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) \u226570 mg\/dL or non-high-density cholesterol \u2265100 mg\/dL despite statin therapy, evolocumab has no impact on patient-reported cognitive function, according to a study published in the May 12 issue of the Journal of the American College of Cardiology<\/i>.<\/p>\n
Baris Gencer, M.D., from Harvard Medical School in Boston, and colleagues studied self-reported cognition in the Further Cardiovascular Outcomes Research With PCSK9 inhibitors in Subjects With Elevated Risk (FOURIER) trial. Patients completed a 23-item survey on memory and executive domains from the Everyday Cognition (ECog) scale at the final visit.<\/p>\n
At a median duration of 2.2 years, 22,655 patients completed ECog. The researchers found that the proportion of patients reporting cognitive decline (ECog score \u22652) was similar for placebo versus evolocumab at the end of the study for total score (3.6 versus 3.7 percent) and for subdomains (memory: 5.8 versus 6.0 percent; total executive, 3.6 versus 3.7 percent). Among the 2,338 patients who achieved very low LDL-C levels (<20 mg\/dL) and the 3,613 with LDL-C \u2265100 mg\/dL, the proportion of patients reporting a decline in total cognitive score was similar (3.8 versus 4.5 percent).<\/p>\n
“These data confirm the neurocognitive safety of intensive LDL-C reduction with evolocumab while reducing recurrent cardiovascular events in high-risk patients, and suggest that very low achieved LDL-C levels may be safely targeted for high-risk patients,” the authors write.<\/p>\n
Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures evolocumab and funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n